Drug eluting coronary stents

POLY 25

Mark Boden, bodenm@bsci.com1, Robert Richard, richardr@bsci.com2, Marlene Schwarz, schwarzm@bsci.com3, and Fred Strickler, stricklf@bsci.com3. (1) Corporate Research & Development, Boston Scientific Corporation, 1 Boston Scientific Place, Natick, MA 01760, (2) Oncology Division, Boston Scientific Corporation, 100 Boston Scientific Way, Marlboro, MA 01752, (3) Corporate Research & Advanced Technology Development, Boston Scientific Corp, One Boston Scientific Place, Natick, MA 01760
The introduction of drug eluting stent technology into the interventional cardiac catheter lab has provided a revolutionary new treatment for cardiovascular re-stenosis. Currently, drug eluting coronary stent technologies are widely available and have demonstrated outstanding results in controlled clinical trials. Drug eluting stents consist of a metal scaffold that is coated with a therapeutic agent dispersed in a polymer that serves to modulate the release of the drug to the artery wall. The requirements for the polymer coating include biocompatibility, biostability as well as mechanical integrity. This presentation will highlight various commercial approaches that have been used to engineer polymer coatings to develop effective solutions to treat coronary artery disease.
 

Polymer Science of Everyday Things
8:25 AM-12:00 PM, Sunday, August 19, 2007 Westin Boston Waterfront -- Otis, Oral

Division of Polymer Chemistry

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007